Navigation Links
MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
Date:12/21/2010

MOUNTAIN VIEW, Calif., Dec. 21, 2010 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced completion of the LEVADEX open-label safety trial.  The Company has now completed the final trial necessary to support a New Drug Application (NDA) for LEVADEX and plans to submit an NDA in the first half of 2011.  LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 clinical development for the acute treatment of migraine.

"We are pleased to have completed the LEVADEX clinical program. This clinical trial completes a comprehensive 505(b)(2) clinical development program which evaluated the efficacy, safety, pharmacokinetics and pharmacodynamics of LEVADEX in approximately 1,000 patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "In 2010, we announced that a second Phase 3 trial would not be necessary for our NDA submission, completed and announced successful results from a pharmacokinetics trial in smokers, a pharmacodynamics trial evaluating pulmonary artery pressure and a thorough QT trial, and we have now completed our open-label safety trial."  

The 12 month open-label, safety extension of the Phase 3 FREEDOM-301 trial was designed to evaluate overall safety of LEVADEX over six and 12 months of exposure.  In total, more than 475 patients completed six months treatment and more than 250 patients completed 12 months treatment.  In this trial no drug-related serious adverse events were reported.

The Company anticipates presenting safety results from the trial at an upcoming scientific conference.  

About LEVADEX™LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO® inhaler. LEVADEX has b
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
2. Lotus Pharmaceuticals Announces Change of Directors
3. Poniard Pharmaceuticals Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
4. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
5. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
6. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. John A. MacPhee Resigns From Strativa Pharmaceuticals
8. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
9. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
11. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014 Imprimis ... pharmaceutical company dedicated to delivering high quality and novel ... announced that Chief Executive Officer Mark Baum ... Annual Craig-Hallum Alpha Select Conference in New York City.  ... its Go Dropless™ campaign in ophthalmology. The presentation ...
(Date:9/16/2014)... -- Relmada Therapeutics, Inc., (OTCBB: RLMD), a clinical-stage company developing ... today that it has entered into an agreement with ... of animal studies for levorphanol, the active ingredient of ... levorphanol.  Gavril Pasternak, MD, PhD, of MSKCC is the ... Pasternak said, "Levorphanol is a unique opioid analgesic that ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
... COLLEGEVILLE, Pa., May 30 Wyeth,Pharmaceuticals, a ... today announced the,initiation of the INTORACT (INvestigation ... worldwide randomized, open-label, phase 3b,study comparing TORISEL(R) ... for first-line treatment of patients,with advanced renal ...
... evaluation of safety and tolerability, as ... 2 trials -, ROCKVILLE, Md., May 30 ... that it has initiated dosing in a Phase,1 clinical ... lead IAP,inhibitor, HGS1029, as monotherapy in patients with advanced ...
Cached Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
(Date:9/16/2014)... Francisco, September 15, 2014A prospective study that compared ... patients with bone metastases demonstrates that single fraction ... multiple fraction radiation therapy (MFRT) when pain, function ... research presented today at the American Society for ... study indicates that improvements in patients, pain, function ...
(Date:9/16/2014)... Texas (PRWEB) September 16, 2014 Beginning October ... adding a new service offering for its clients who book ... to the volume of business they buy. Most recurring ... during the work week, but others include clients whose ... pet sitter on a daily basis. The ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral candidate Steve ... fighting to legalize medical marijuana in Florida. Advocating for ... recently commissioned a shot-for-shot parody video of the song ... “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re the Law ... faithfully recreates the carnival scene made famous by John ...
(Date:9/16/2014)... Florida Hospital announced today it is teaming ... partnership and become the Presenting Sponsor of the 2014-15 ... health and wellness partner. As the Presenting Sponsor for ... logo and name inclusion on all Lightning advertising campaigns ... has been a sponsorship partner of the Lightning since ...
(Date:9/16/2014)... reduce the risk of heart disease or stroke, even ... part of the diet. , A study of ... from Monash University,s Department of Epidemiology and Preventive Medicine ... consumption of dairy foods had played in the country,s ... dominantly Chinese food culture, unaccustomed to dairy foods, consuming ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... Large study suggests the procedure impairs healthy immune response ... by Caesarean section are at increased risk of asthma, ... the respiratory health of nearly 3,000 infants. , By ... percent) of the children had been diagnosed with asthma ...
... the year. , ... (PRWEB) November 2, 2009 -- For the ... treatment Frontline , to UK mainland addresses, excluding the highlands and islands, ... the Hyperdrug.co.uk web site. , , ,Hyperdrug director Ben Watson says "Hyperdrug ...
... INDIANAPOLIS, Dec. 3 Vertellus Specialties Inc., a leading specialty ... January 1, 2009 for 2-vinylpyridine monomer sales to all non-contract ... investment in production capacity and to provide better supply chain ... About Vertellus Specialties Inc. ...
... positive airway pressure (CPAP) treatment seems to improve cognitive ... from obstructive sleep apnea, according to the results of ... California, San Diego. The study led by Sonia ... Diego School of Medicine and one of the nation,s ...
... the availability of Trade Alerts on stocks making news today. , ... notes for free by visiting: http://www.BeaconEquity.com/m , , ... ), Williams-Sonoma Inc. (NYSE: WSM ), Medicis Pharmaceutical Corp. (NYSE: ... Group Co. (Nasdaq: MHGC ) and DSP Group Inc. (Nasdaq: ...
... the body to selectively suppress the immune response may ... to scientists. , "If you like, what we are ... more like a fetus," said Dr. Andrew L. Mellor, ... and Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics. ...
Cached Medicine News:Health News:C-Section Might Boost Baby's Asthma Risk 2Health News:Beating the Credit Crunch with Hyperdrug.co.uk 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 2Health News:Treating sleep apnea in Alzheimer's patients helps cognition 3Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: SPC, WSM, MRX, WXS, MHGC, DSPG 2Health News:New approaches to protecting transplanted organs make first steps toward patients 2Health News:New approaches to protecting transplanted organs make first steps toward patients 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: